MRNA vaccine
 | This article needs additional citations for verification. (February 2020) |
An RNA vaccine is a novel type of vaccine which is composed of the nucleic acid RNA, packaged within a vector such as lipid nanoparticles[1]. No RNA vaccines have yet been approved for medical use, though clinical trials are ongoing[2].
Just like normal vaccines, RNA vaccines are intended to induce the production of antibodies which will bind to potential pathogens. This is accomplished when the RNA from the vaccine (a messenger RNA) is delivered into cells in the body, which then produce proteins that resemble or are identical to proteins from the pathogen. These proteins are then used by the body’s immune system to produce antibodies against the pathogen, causing future protection from the pathogen.[3]
See also
References
- ^ "mRNA Platform". CureVac. Retrieved 2020-03-21.
{{cite web}}: CS1 maint: url-status (link) - ^ Zhang, Cuiling; Maruggi, Giulietta; Shan, Hu; Li, Junwei (2019). "Advances in mRNA Vaccines for Infectious Diseases". Frontiers in Immunology. 10. doi:10.3389/fimmu.2019.00594. ISSN 1664-3224.
{{cite journal}}: CS1 maint: unflagged free DOI (link) - ^ Hubaud, Alexis. "RNA vaccines: a novel technology to prevent and treat disease". sitn.hms.harvard.edu. Harvard University. Retrieved 17 February 2020.